Mymd Pharmaceuticals (QCLS) vs. The Competition Head-To-Head Contrast

Mymd Pharmaceuticals (NASDAQ:QCLS) is one of 81 publicly-traded companies in the “Technology Hardware, Storage & Peripherals” industry, but how does it weigh in compared to its rivals? We will compare Mymd Pharmaceuticals to similar businesses based on the strength of its institutional ownership, analyst recommendations, dividends, earnings, valuation, risk and profitability.

Insider and Institutional Ownership

9.6% of Mymd Pharmaceuticals shares are held by institutional investors. Comparatively, 51.5% of shares of all “Technology Hardware, Storage & Peripherals” companies are held by institutional investors. 0.9% of Mymd Pharmaceuticals shares are held by company insiders. Comparatively, 10.8% of shares of all “Technology Hardware, Storage & Peripherals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Mymd Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mymd Pharmaceuticals	N/A	-88.18%	-42.59%
Mymd Pharmaceuticals Competitors	-564.27%	-14.59%	4.09%

Analyst Ratings

This is a summary of current ratings and recommmendations for Mymd Pharmaceuticals and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mymd Pharmaceuticals	1	0	0	0	1.00
Mymd Pharmaceuticals Competitors	1043	4275	7538	357	2.55

As a group, “Technology Hardware, Storage & Peripherals” companies have a potential upside of 13.15%. Given Mymd Pharmaceuticals’ rivals stronger consensus rating and higher probable upside, analysts plainly believe Mymd Pharmaceuticals has less favorable growth aspects than its rivals.

Risk & Volatility

Mymd Pharmaceuticals has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Comparatively, Mymd Pharmaceuticals’ rivals have a beta of 1.55, meaning that their average share price is 55% more volatile than the S&P 500.

Earnings & Valuation

This table compares Mymd Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mymd Pharmaceuticals	N/A	-$11.63 million	-0.14
Mymd Pharmaceuticals Competitors	$23.93 billion	$3.70 billion	6.60

Mymd Pharmaceuticals’ rivals have higher revenue and earnings than Mymd Pharmaceuticals. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Mymd Pharmaceuticals rivals beat Mymd Pharmaceuticals on 11 of the 13 factors compared.

Mymd Pharmaceuticals Company Profile

TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.